Multicenter Study to Evaluate Efficacy, Tolerability, Safety of Derinat

NCT04149431 | Unknown Phase 3 DMC

• 1 other identifier: ДК-18
• Study Type: interventional
• Target: 350
• Locations: 1 country
• Sites: 1

Brief Summary

This multicenter prospective double blinded placebo-controlled randomized study is designed to to evaluate clinical efficacy, tolerability and safety of medical product Derinat®, solution for external and local use 0.25% in acute infections of respiratory system in children

Conditions

Respiratory Infections in Children

Keywords

Derinat; Respiratory infection; Children

Outcome Measures

Primary Outcomes (1)

• Superiority of Derinat

  Assessment of frequency of resolution of symptoms of acute respiratory infection of the upper respiratory tract confirmed by the absence of symptoms (0 points on the scale of evaluation of symptoms of acute upper respiratory infection during at least 24 hours

  through study completion, an average of 30 days

Secondary Outcomes (2)

• Efficacy of Derinat

  through study completion, an average of 30 days

• Safety of Derinat

  through study completion, an average of 30 days

Study Arms (2)

Derinat

ACTIVE COMPARATOR

nasal drops

Drug: Derinat

Placebo

PLACEBO COMPARATOR

nasal drops

Drug: Derinat

Interventions

Derinat DRUG

desoxyribonucleate sodium

Also known as: desoxyribonucleate sodium

Derinat; Placebo

Eligibility Criteria

• Age: 1 Day - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Signed informed consent
• Male and female patients.
• The age of the child at the time of first intranasal administration of drug for age group 1: 12 years to \<18 years; for age group 2: from 6 years to \<12 years; for age group 3: from 2 years to \<6 years; for age group 4: 7 months to \<2 years; for age group 5: from 0 months to 6 months.
• Outpatient and inpatient patients hospitalized for epidemiological reasons, with a diagnosis of acute respiratory infection of the upper respiratory tract of mild to moderate severity. (ICD 10: J00 - J06 Acute respiratory infections of the upper respiratory tract).
• The positive result of the enzyme immunoassay express test for pathogens of acute respiratory infection of the upper respiratory tract on screening.
• At least one episode of body temperature up to 38C and above within 48 hours prior to screening.
• Presence of at least one of the following mild to moderate symptoms at screening: headache, weakness/malaise, muscle pain/aching, feeling of heat/chills.
• The duration of the disease is not more than 48 hours at the time of screening according to the patient/parents/adoptive parents.
• Adequate contraceptive methods during the study for the patients with childbearing potential

You may not qualify if:

• Positive express test (in urine) for pregnancy in patients with childbearing potential (menarche).
• Individual intolerance or hypersensitivity to any of the components of the drug according to the medical history.
• Taking any drugs with immunomodulatory effect less than 30 days before screening according to medical history.
• The presence of complications of acute respiratory infection of the upper respiratory tract, signs of severe disease at the time of screening (fever more than 39ºC, febrile convulsions).
• Acute infectious diseases: diphtheria, measles, infectious mononucleosis, herpes type 1 and 2, rubella, scarlet fever, acute BGSA-tonsillopharyngitis at the time of screening or 30 days before screening.
• Chronic diseases of the respiratory system (Bronchial asthma, COPD).
• HIV infection, chronic viral hepatitis B or C (according to history).
• Impaired renal function with serum creatinine level more than 1.5 times higher than the upper limit of the normal range.
• Severe liver failure or active liver disease (including viral hepatitis B or C) and increase of ALT and AST more than 5 times of upper limit of the normal range.
• Participation in any clinical trials and / or taking an experimental drug within 30 days prior to the screening visit.
• Other significant diseases and conditions of the patient, including mental and physical diseases

Sponsors & Collaborators

• PharmPak, LLC: lead

Study Sites (1)

Irina Gerasimova

Moscow, Russia

Location

MeSH Terms

Conditions

Respiratory Tract Infections

Interventions

Derinat

Condition Hierarchy (Ancestors)

Infections; Respiratory Tract Diseases

Study Officials

• Irina Gerasimova, Dr.

  PharmPak, LLC

  STUDY DIRECTOR

Central Study Contacts

Irina Gerasimova, Dr.

CONTACT

+79168008485; gerasimova@derinat.ru

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: double blind randomized placebo controlled study
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This is a multi-center, double-blind, randomized phase III-IV clinical trial in parallel groups to evaluate the efficacy and safety of Derinat versus Placebo in patients with acute upper respiratory tract infection.

Study Record Dates

• First Submitted: October 16, 2019
• First Posted: November 4, 2019
• Study Start: December 15, 2019
• Primary Completion: May 31, 2022
• Study Completion: May 31, 2022
• Last Updated: November 4, 2019

Record last verified: 2019-10

Locations

RU (1)